Haemonetics Corp. [HAE] stock prices are up 0.39% to $77.75 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The HAE shares have gain 6.54% over the last week, with a monthly amount glided 0.84%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 5, March 2024, Haemonetics Announces Definitive Agreement to Acquire Attune Medical. In a post published today on Yahoo Finance, Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical products and solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to acquire privately-held Chicago-based Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device, the only FDA-cleared temperature regulation device indicated for esophageal protection during radiofrequency (RF) cardiac ablation procedures.
From an analyst’s perspective:
Haemonetics Corp. [NYSE: HAE] stock has seen the most recent analyst activity on October 13, 2022, when Mizuho initiated its Buy rating and assigned the stock a price target of $90. Previously, Needham downgraded its rating to Hold on January 27, 2022. On December 15, 2021, downgrade downgraded it’s rating to Neutral and revised its price target to $59 on the stock. Citigroup initiated its recommendation with a Buy and recommended $75 as its price target on June 17, 2021. CJS Securities upgraded its rating to Market Outperform for this stock on May 14, 2021. In a note dated April 20, 2021, Morgan Stanley downgraded an Equal-Weight rating on this stock.
The stock price of Haemonetics Corp. [HAE] has been fluctuating between $70.74 and $95.26 over the past year. Haemonetics Corp. [NYSE: HAE] shares were valued at $77.75 at the most recent close of the market.
Analyzing the HAE fundamentals
The Haemonetics Corp. [NYSE:HAE] reported sales of 1.27B for trailing twelve months, representing a surge of 10.14%. Gross Profit Margin for this corporation currently stands at 0.53% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.13%, and Net Profit Margin reading is 0.1%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.14 and Total Capital is 0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.92.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 77.31 points at the first support level, and at 76.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 78.38, and for the 2nd resistance point, it is at 79.01.
Haemonetics Corp. [HAE] reported earnings per share of $1.04 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.94/share, meaning a difference of $0.1 and a surprise factor of 10.60%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.99 per share as compared to estimates of $0.89 per share, a difference of $0.1 representing a surprise of 11.20%.
Ratios To Look Out For
It’s worth pointing out that Haemonetics Corp. [NYSE:HAE]’s Current Ratio is 2.92. On the other hand, the Quick Ratio is 1.76, and the Cash Ratio is 0.74. Considering the valuation of this stock, the price to sales ratio is 3.11, the price to book ratio is 4.19 and price to earnings (TTM) ratio is 31.54.
Transactions by insiders
Recent insider trading involved Strong Stewart W, President, Global Hospital, that happened on Sep 12 ’23 when 228.0 shares were sold. EVP, Chief Technology Officer, Lingamneni Anila completed a deal on Sep 11 ’23 to sell 2305.0 shares. Meanwhile, Director Dockendorff Charles J sold 10215.0 shares on Sep 05 ’23.
